AG Prof. C. Bogdan

Weitere Informationen auf unserer englischen Webseite

Publikationen

1. Rai B, Barinberg D, Chunguang L, Debus A, Rauh M, Kirici S, Sebald H, Grotz M, Gold T, Kunz M, Bozec A, Mattner J, Roberts S, Becker I, Bogdan C*, Schleicher U*. (2025). Oral L-arginine cures arginase 1-dependent chronic cutaneous leishmaniasis by redirecting the T helper cell response. bioRxiv 10.1101/2025.09.23.677696 https://www.biorxiv.org/content/10.1101/2025.09.23.677696v1(*shared senior and corresponding authorship)
2. Barinberg D, Sebald H, Gold T, Rai R, Radtke D, Lerm D, Voehringer D, Jantsch J, Wirtz S, Antonova AU, Colonna M, Bogdan C*, Schleicher U*. (2025). The metabolic program of inflammatory eosinophils accounts for chronic parasite-induced skin disease. bioRxiv 2025.02.28.640104; doi: https://doi.org/10.1101/2025.02.28.640104  (*shared senior and corresponding authorship)
3. Esse J, Träger J, Steininger P, Bihlmaier K, Fürst J, Bardonicsek-Depnering Z, Naumann-Bartsch N, Morhart P, Castellanos I, Krause SW, Herbst L, Strauß R, Chada M, Korn K, Valenza G, Teschner D, Bogdan C, Held J. (2025). Metagenomic analysis of microbial cell-free DNA from plasma of patients with suspected infections: performance and therapeutic impact in clinical routine.Clin Microbiol Infect. 2025 Jun;31(6):1018-1025. doi: 10.1016/j.cmi.2025.02.016.
4. Bogdan C, Islam NA, Barinberg D, Soulat D, Schleicher U, Rai B. (2024). The immunomicrotope of Leishmania control and persistence. Trends Parasitol 40: 788-804. 10.1016/j.pt.2024.07.013.
5. Lai C, Heinemann J, Schleicher U, Schett G, Bogdan C, Bozec A, Soulat D. Chronic Systemic Infection of Mice with Leishmania infantum Leads to Increased Bone Mass. J Bone Miner Res. 2023 Jan;38(1):86-102. doi: 10.1002/jbmr.4733. Epub 2022 Nov 16.
6. Debus D, Genç S, Kurz P, Holzer M, Bauer K, Heimke-Brinck R, Baier M, Sebald H, Debus A, Bogdan C, Stahl KW. Case Report: Local Treatment of a Leishmania tropica Infection in a Syrian Child with a Novel Filmogenic Preparation of Pharmaceutical Sodium Chlorite (LeiProtect®). Am J Trop Med Hyg. 2022 Jan 10;106(3):857-860. doi: 10.4269/ajtmh.21-0962.
7. Sasse C, Barinberg D, Obermeyer S, Debus A, Schleicher U, Bogdan C. Eosinophils, but Not Type 2 Innate Lymphoid Cells, Are the Predominant Source of Interleukin 4 during the Innate Phase of Leishmania major Infection. Pathogens 2022 Jul 25;11(8):828. doi: 10.3390/pathogens11080828.
8. Bogdan C.Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism. Cytokine X. 2020 Oct 12;2(4):100041. doi: 10.1016/j.cytox.2020.100041. eCollection 2020 Dec.
9. Paduch K, Debus A, Rai B, Schleicher U, Bogdan C. Resolution of cutaneous leishmaniasis and persistence of Leishmania major in the absence of arginase 1. J Immunol. 2019 Mar 1;202(5):1453-1464. doi: 10.4049/jimmunol.1801249. Epub 2019 Jan 21.
10. Bogdan C, Debus A, Sebald H, Rai B, Schäfer J, Obermeyer S, Schleicher U. Experimental Cutaneous Leishmaniasis: Mouse Models for Resolution of Inflammation Versus Chronicity of Disease. Methods Mol Biol. 2019;1971:315-349. doi: 10.1007/978-1-4939-9210-2_18.
11. Messlinger H, Sebald H, Heger L, Dudziak D, Bogdan C and Schleicher U. (2018). Monocyte-derived signals activate human natural killer cells in response to Leishmania  parasites. Frontiers in Immunology epublished January 24, 2018: doi: 10.3389/fimmu.2018.00024.
12. Schleicher U, Liese J, Justies N, Mischke T, Haeberlein S, Sebald H, Kalinke U, Weiss S and Bogdan C. (2018). Type I interferon signaling is required for CpG-oligodesoxy-nucleotide-induced control of Leishmania major, but not for spontaneous cure of subcutaneous cure of primary and secondary L. major infection. Frontiers in Immunology epublished January 11, 2018: doi: 10.3389/ fimmu.2018.00079.
13. Schleicher U., Paduch K., Debus A., Obermeyer S., König T., Kling J.C., Ribechini E., Dudziak D., Mougiakakos D., Murray P.J., Ostuni R., Körner H. and Bogdan C  (2016). TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection. Cell Reports 15: 1062-75.
14. Bogdan C (2015) Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol 36: 161-178
15. Schleicher U, Liese J, Knippertz I, Kurzmann C, Hesse A, Heit A, Fischer JA, Weiss S, Kalinke U, Kunz S, Bogdan C (2007). NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of pDCs. J Exp Med. 204: 893-906.